U 84793Alternative Names: FK-2P
Latest Information Update: 15 Jun 1995
At a glance
- Originator Pharmacia Corporation
- Class Thrombolytics
- Mechanism of Action Plasminogen activator inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 15 Jun 1995 No-Development-Reported for Thrombosis in USA (Unknown route)